

26. (New) The method according to claim 19, wherein the monoclonal antibody specific for the amino acid sequence of SEQ ID NO: 2 is specific for amino acid residues 20-35 of SEQ ID NO: 2.

27. (New) The method according to claim 19, wherein the monoclonal antibody specific for the amino acid sequence of SEQ ID NO: 3 is specific for amino acid residues 5-10 of SEQ ID NO: 3.

C1  
28. (New) The method according to claim 19, wherein the monoclonal antibody specific for the amino acid sequence of SEQ ID NO: 2 is specific for amino acid residues 6-38 of SEQ ID NO: 2 and wherein the monoclonal antibody specific for the amino acid sequence of SEQ ID NO: 3 is specific for amino acid residues 5-10 of SEQ ID NO: 3.

29. (New) The method according to claim 19, wherein the monoclonal antibody specific for the amino acid sequence of SEQ ID NO: 2 is specific for amino acid residues 20-35 of SEQ ID NO: 2 and wherein the monoclonal antibody specific for the amino acid sequence of SEQ ID NO: 3 is specific for amino acid residues 5-10 of SEQ ID NO: 3.

---

#### REMARKS

Applicants submit this Amendment in response to the Office Action dated May 7, 2002. Claims 19-24 are currently under consideration in the present application. Claims 25-29 are newly added. It is urged that support for the above amendments can be found throughout the specification as originally filed and that none of the amendments constitute new matter. More specifically, the amino acid residues within SEQ ID NOs: 2 and 3 that are recited in new claims 25-29 derive specific support from the specification as filed, wherein these claimed sequences are disclosed as specific sub-sequences within SEQ ID NOs: 2 and 3 that possess important antibody binding properties in common with SEQ ID NOs: 2 and 3 (see, *e.g.*, page 4, lines 11-19 and page 8, lines 1-5 of WO 98/01471, from which the instant application claims priority under 35 U.S.C. § 371). It should also be noted that the above amendments are not to be construed as